Lose up to 20%* of your body weight with this simple, weekly GLP-1+GIP tailored just to you
Avoiding a single knee replacement surgery would pay for nearly seven years of retatrutide treatment
The number of Medicaid prescriptions and gross spending on GLP-1s have increased substantially since 2019 (Figure 2)
GLP-1 agonists demonstrate potential beyond metabolic benefits, targeting inflammatory mechanisms underlying ulcerative colitis through pathways observed in preclinical research. For overweight patients with ulcerative colitis, these medications offer dual benefits: reducing inflammation while facilitating weight loss , which itself may decrease disease activity
Losing weight through Semaglutide treatment can significantly reduce the risk of developing weight-related conditions such as type 2 diabetes, high blood pressure, and heart disease
For example, if you develop a rash, hives, or wheezing (signs of an allergic reaction), or if you feel chest tightness or have difficulty swallowing, seek medical attention immediately